BBLGW Bone Biologics Corp - warrants
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts. This security was issued by Bone Biologics Corp., whose common stock symbol is BBLG.
$0.04 -0.01 (-21.57%)
As of 03/20/2023 16:00:00 EST IEX book CBOE book
Security Information
Category1: US Equity
Category2: Warrants
Category3: Operating Companies
GICS sector: Health Care
Industry: Medical Devices
Index country: USA
Country of incorporation:
IPO date: 10/13/2021
Outstanding shares: 950,000
Average volume: 1,378
Market cap: $2,442,737
Current dividend yield: 0.00%
All SEC filings: SEC Edgar Online
Quarterly filings: 10-Q
Annual filings: 10-K
Sedol: